NME
ALXN

Notis-McConarty Edward’s Alexion Pharmaceuticals ALXN Stock Holding History

Notis-McConarty Edward’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-750
Closed -$117K – 110
2015
Q3 		$117K Hold
750
– – 0.09% 107
2015
Q2 		$136K Hold
750
– – 0.09% 112
2015
Q1 		$130K Hold
750
– – 0.09% 112
2014
Q4 		$139K Hold
750
– – 0.1% 111
2014
Q3 		$124K Buy
+750
New +$123K 0.09% 112

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Notis-McConarty Edward's ALXN Position: Q4 2015 in Review

Notis-McConarty Edward sold out of Alexion Pharmaceuticals (ALXN) in Q4 2015, closing a stake of 750 shares — an estimated $117K sold.

Notis-McConarty Edward first reported a position in ALXN in Q3 2014 and held it in 5 quarters. The position peaked at $139K in Q4 2014. 547 funds tracked by Wall St. Rank hold ALXN as of Q4 2015.

  • Notis-McConarty Edward reported no remaining Alexion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Notis-McConarty Edward sold 750 Alexion Pharmaceuticals shares in Q4 2015, an estimated $117K.
  • Notis-McConarty Edward first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 5 quarters.
  • Notis-McConarty Edward's Alexion Pharmaceuticals position peaked at $139K in Q4 2014.
  • 547 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2015.

Based on Notis-McConarty Edward's 13F filing for Q4 2015, filed 12 Feb 2016.